Anti-hIFNAR-hIgG1-FES
-
Cat.code:
hifnar-mab16
- Documents
ABOUT
Anti-human IFNAR1 - Anifrolumab biosimilar - CAS #1326232-46-5
Anti-hIFNAR-hIgG1-FES is the biosimilar antibody of Anifrolumab, a human type I interferon (IFN) receptor subunit 1 (IFNAR1) antibody that inhibits type I IFN signaling. This monoclonal antibody (mAb) is FDA-approved for the treatment of systemic lupus erythematosus (SLE).
Anti-hIFNAR-hIgG1-FES comprises the variable region of Anifrolumab and the effectorless IgG1 constant region of Anifrolumab harboring a triple mutation L234F/L235E/P331S (FES).
This antibody can be used together with HEK-Blue™ IFN-α/β cells for screening and neutralization assays to inhibit IFN-α/β signaling induced by recombinant human IFN-α or IFN-β (see figure).
Key features
- Each lot is functionally tested and validated
- The complete sequence of the antibody construct has been verified
- The absence of endotoxins is determined by the EndotoxDetect assay
If you are interested in the corresponding isotype control Anti-β-Gal-hIgG1-FES mAb, please contact us.
All products are for research use only, and not for human or veterinary use.
InvivoGen also offers:
SPECIFICATIONS
Specifications
IFNAR1
Human
Sodium phosphate buffer with glycine, saccharose, and stabilizing agents
Negative (tested using EndotoxDetect™ assay)
Neutralization assay, ELISA, Fc effector function analysis
Each lot is functionally tested and validated.
CONTENTS
Contents
-
Product:Anti-hIFNAR-hIgG1-FES
-
Cat code:hifnar-mab16
-
Quantity:100 µg
Shipping & Storage
- Shipping method: Room temperature
- -20°C
- Avoid repeated freeze-thaw cycles
Storage:
Caution:
Details
Anifrolumab background
Anifrolumab is a fully human mAb designed to target the type I interferon (IFN) receptor subunit 1 (IFNAR1) and to block the type I IFN signaling. Anifrolumab features a triple mutation L234F/L235E/P331S in the heavy chain to reduce engagement with the cell surface Fc gamma receptor (FcγR) and potential Fc-mediated effector function, such as antibody-dependent cell-mediated cytotoxicity (ADCC) [1-2]. According to the FDA, it is a first-in-class medication highlighting its innovative and unique mechanism of action [3]. It has been approved as an add-on therapy for moderately to severely active systemic lupus erythematosus (SLE) [3].
References:
1. Plüß M, et al., 2022. Rapid Response of Refractory Systemic Lupus Erythematosus Skin Manifestations to Anifrolumab-A Case-Based Review of Clinical Trial Data Suggesting a Domain-Based Therapeutic Approach. J Clin Med. 11(12):3449.
2. Riggs JM, et al., 2018. Characterization of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus. Lupus Sci Med. 5(1):e000261.
3. U.S. Food and Drug Administration (FDA) (Report). 2022. Advancing Health Through Innovation: New Drug Therapy Approvals 2021.
DOCUMENTS
Documents
Technical Data Sheet
Validation Data Sheet
Safety Data Sheet
Certificate of analysis
Need a CoA ?
